Latest filing published 08 Sept 2021 for Inmune Bio, Inc., €709k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Xencor Inc: trading record in brief
Xencor Inc discloses dealings in Inmune Bio, Inc. to SEC (Form 4). Over a trading history stretching from 10 June 2021 to 3 September 2021, the count stands at 4 filings.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The latest filing, published on 8 September 2021, reports a transaction of €2.7M in Inmune Bio, Inc. Filings reach the SEC (Form 4) feed a median of 48 days after the trade. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Xencor Inc
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 108,000 shares@ US$7.8011.6% of flowCommon StockSEC:0001415889-21-004281:0
- 192,533 shares@ US$17.146.58% mcap15.3% of flowCommon StockSEC:0001415889-21-004279:0
- 192,533 shares@ US$17.1444.2% of flowCommon StockSEC:0001415889-21-004280:0
- 192,532 shares@ US$17.1444.2% of flowCommon StockSEC:0001415889-21-002991:0
4 of 4 declarations